IMPACT: A phase IV multicentre cross-sectional-study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir

Trial Profile

IMPACT: A phase IV multicentre cross-sectional-study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 May 2006

At a glance

  • Drugs Antiretrovirals; Atazanavir; Ritonavir
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Acronyms IMPACT
  • Most Recent Events

    • 18 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top